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Cell therapy and regenerative medicine technologies require strict cell manufacturing procedures to be
deﬁned and addressed. Maintenance of the aseptic environment is critical to preclude extrinsic
contamination risks, similar to conventional pharmaceutical manufacturing. However, intrinsic
contamination risks exist in all cell manufacturing processes owing to the use of cells as the raw ma-
terials that cannot be sterilized, thus giving rise to the primary and secondary risks of cell contamination
and cross-contamination, respectively. Analysis of contamination risks was conducted on experienced
batches (29,858 batches) for the production of immune cells derived from autologous blood mono-
nuclear cells under the Medical Practitioners Act and the Medical Care Act in Japan. From these batches,
0.06% (18 cases) of contamination occurred, representing low probability of contamination incidence
during cell processing. Almost all the causes of these contaminations were regarded to be from the
collected blood (intrinsic contamination), and subsequent cross-contaminations were prevented,
considering that the secondary contamination risk can be reduced by adequate managements of oper-
ational procedures for changeover in aseptic environment.
© 2016, The Japanese Society for Regenerative Medicine. Production and hosting by Elsevier B.V. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).1. Introduction
A new regulatory framework for regenerative medicine
including cell therapies has been implemented in Japan by two
new laws that came into effect on November 25, 2014. There are
known as the ‘The Act on the Safety of Regenerative Medicine’ in
the Medical Practitioners Act, and the Medical Care Act, and the
‘Pharmaceuticals, Medical Devices and Other Therapeutic Products
Act’ in the Pharmaceutical Affairs Act [1,2]. These laws are
considered to expedite the industrialization of services for
regenerative medicine [3], and many companies have already
entered cell/tissue manufacturing ﬁelds. However, experience is
limited for quality management in manufacturing living cell/tissue
products. Consequently, many hurdles exist to overcome thetechnology, Graduate School
ta, Osaka, 565-0871, Japan.
. Mizutani).
se Society for Regenerative
ative Medicine. Production and homanufacturing of regenerative medicine products, compared with
in conventional aseptic pharmaceutical manufacturing.
To produce cells in terms of safety as well as efﬁcacy, cell
manufacturing is a critical step to consider. Aseptic assurance is an
important factor for manufacturing living cell/tissue products that
cannot be sterilized. The quality system for aseptic manufacturing
is planned around area design in the cell processing facility (CPF)
for adequate maintenance of cleanness, and operational manage-
ment to preclude extrinsic contamination risks in the process,
similar to conventional pharmaceutical manufacturing. However,
at initiation of human cell processing, the raw material has an
intrinsic contamination risk from microorganisms originating
from the donor or the environment during biopsy harvesting.
This intrinsic contamination brings a primary risk in the
cell manufacturing process, leading to secondary risk of cross-
contamination to other products.
Cross-contamination is causedmainly in twoways; a splash mist
of waste medium from the original culture vessel transferred
directly through the air ﬂow in a biosafety cabinet (BSC) into others
during medium change operation, or the mist adheres onto the BSCsting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
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vessels. Detection of cross-contamination is often delayed, leading
to a broader expansion of contamination, which is a critical concern.
During autologous cell processing in Japan, the manufacturing
process is currently carried out manually in a commercial BSC, and
cultures of multiple patient cells are handled sequentially in a
single BSC, which differs substantially from typical pharmaceutical
manufacturing methods. The prevention of intrinsic contamination
risks is one critical issue in autologous cell processing, and the
prevention of cross-contamination during changeover, which re-
quires cleaning after the completion of operation for each culture, is
an important procedure for quality control [4].
Although many cell manufacturing cases exist for clinical
treatment under the Medical Practitioners Act and Medical Care
Act, experience of cell manufacturing under the Pharmaceutical
Affairs Act is not extensive in Japan. Therefore shared knowledge in
practical manufacturing is invaluable for the design of quality
management. The Biotherapy Institute of Japan (BIJ) has manufac-
tured approximately 30,000 batches of cells in the latest 5 years for
immunotherapy within various clinical institutions. During the
preparation of activated immune cells from peripheral blood at BIJ,
the occurrence of contamination by proliferative microorganisms is
observed visually, because no antibiotics are added to the culture
medium during any stage of the process. Therefore, this study
aimed to predict whether contamination risks during autologous
cell manufacturing could be determined by conﬁrming the
contamination periods and sources observed during operation.2. Materials and methods
2.1. Design of clean areas in the CPF
The ﬂoor plan of the CPF at BIJ, which has previously been used
to manufacture cells, is shown (Fig. 1). Brieﬂy, three cell processingISO class 5 ISO class 8
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Fig. 1. Three cell processing rooms in the facility included the operating areas (cleanliness IS
clean corridor with a changing room (cleanliness ISO class 8). There were a total of 18 aseprooms exist, consisting of the aseptic area in a BSC (cleanliness ISO
class 5) and a cell processing area (cleanliness ISO class 7), coupled
with anterior/posterior buffer areas, isolated from the outside
environment by a clean corridor with a changing room (cleanliness
ISO class 8). Six BSCs were installed in each cell processing area.
Thus 18 aseptic areas of BSCs were installed in the CPF for cell
manufacturing.
2.2. Operational procedure in the cell processing room
In each cell processing room, one operator was engaged at a
single BSC, with up to six operators entering one room at the same
time. Each operator wore a whole-body lint-free suit, with a mask
and gloves, and was then able to treat cells in the aseptic area. A
centrifuge and four CO2 incubators, with a BSC, were used by one
operator as an individual operating area (Figs. 2 and 3). Operators
were able to carry around culture vessels only in the range of the
operating area to avoid any intersection of the operational ﬂow
lines. All culture vessels conformed to an airtight system, and open
operations were carried out only in aseptic areas. After each oper-
ation, the operator cleaned the operating area using a certiﬁcated
disinfecting procedure and sterilant to complete the changeover
process in preparation for the next operation. Each operator
handled a single batch during an operation and was not allowed to
make parallel operations for multiple batches.
2.3. Expansion of activated immune cells
The procedure for the expansion of activated immune cells us-
ing an expansion kit (BINKIT®, BIJ, Japan) is described below [5,6]. A
description of the quality tests used to analyze surface markers
is omitted in this report. Blood mononuclear cells were isolated
from 50 mL of peripheral blood by density gradient centrifugation
using Ficoll-Paque (GE Healthcare, Sweden). A tiny quantity of thedoor airtightdoor pass box
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Fig. 2. Six BSCs, were used as the aseptic areas for operation in each cell processing room. A centrifuge, four CO2 incubators, and a BSC were used by one operator as an individual
operating area. The ﬂow line for each individual operating area was isolated from the common ﬂow line.
Fig. 3. Each ﬂow line in the operating area was designed not to cross each other, and
the other operators could not approach the area of the operator that had processed the
cells at the BSC. The changeover process of each operating area was carried out after
disinfection.
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the infection of fungi or bacteria by culture method at 30 C using a
sheep blood agar plate (Eiken Chemical, Japan). The isolated pe-
ripheral blood mononuclear cells were cultured in BINKIT® initial
medium, in a BINKIT® culture ﬂask for initial activation, with the
addition of 5% heat-inactivated autologous plasma in a BINKIT®
initial cocktail. Antibiotics, antibacterial or antifungal agents were
not contained in the BINKIT® expansion kit. After 3 days of culti-
vation for activation, the cells were transferred to a culture ﬂask
containing BINKIT® subculture medium. Fresh culture mediumwas
added to the ﬂask every 2 or 3 days. When the number of cultured
cells started to logarithmically increase, the cells were transferredto a culture bag (NIPRO, Japan) until the end of culture. Incubation
was performed at 37 C in a humidiﬁed atmosphere of 5% CO2 in air
using an incubator (Astec, Japan). The total culture period was
around 3 weeks, and activated immune cells proliferated to
approximately 2  109 cells, with patient variability. After ﬁlling an
infusion bag (Terumo, Japan) with Ringer's solution (Otsuka Phar-
maceutical, Japan), the ﬁnal product was shipped to the medical
institution. For all ﬁnal products, a sterility test, a mycoplasma
negative test, and an endotoxin test were carried out. Brieﬂy, an
infection of fungi and bacteria was checked by plating method at
30 C culture by using soybean-casein digest [SCD] medium (Eiken
Chemical, Japan), which the culture period was up to 2 weeks.
Mycoplasma detection was conducted by polymerase chain reac-
tion [PCR] method using Cycleave® PCR Mycoplasma Detection Kit
(Takara Bio, Japan). The sensitivity of endotoxinwas checked by gel-
clot method of limulus amebocyte lysate [LAL] assay using Limulus
ES-2 Test wako (Wako Pure Chemical, Japan). The positive sample
would be rechecked for quantify by turbidimetric method when
gelation was found.
2.4. Detection of fungi and bacteria contamination
The occurrence of contamination by proliferating fungi and
bacteria during the process was detected by visual observation. At
the start of each process, the operator conﬁrmed the transparency,
color and pH of the medium. If either the transparency or pH was
changed from the reference, the turbid state and the culture day
were recorded alongside conﬁrmation. A sample solution of the
medium was harvested to determine if contamination had
occurred. If contamination was conﬁrmed, the type of bacteria or
fungal contaminated source was identiﬁed by direct microscopy of
the microbiological culture.
2.5. Classiﬁcation of contamination cases by manufacturing phase
The timing of contamination was classiﬁed into early, middle
and late phases by culture days when a turbid state was recognized.
The early phase was deﬁned in the range of processing time up to 3
days for expansion, including the cell isolation and primary culture
for activating the separated mononuclear cells. The middle phase
was deﬁned in the range from 3 to 7 days, including passage culture
Table 2
Contamination incidence observed in the manufacturing process.
Phase of the process Culture days Year Total
2010 2011 2012 2013 2014
Early phase 1e3 0 2 0 3 0 5
Middle phase 4e10 3 3 5 0 2 13
Late phase 11~ 0 0 0 0 0 0
Subtotal 3 5 5 3 2 18
M. Mizutani et al. / Regenerative Therapy 5 (2016) 25e3028up to the point of bag culture processing. The late phase was the
remaining period until the end of the manufacturing process.
3. Results
3.1. Incidence of contamination in the manufacturing process
To prepare activated immune cells for clinical use 29,858
batches were manufactured in a CPF at BIJ during ﬁve years from
2010 to 2014 (Table 1). Cell processing of more than 15 batches was
carried out daily in each BSC. Identiﬁcation of fungi and bacteria
for the ﬁnal product was performed by sampling the culture me-
dium before shipment, and check for mycoplasma infection and
endotoxin assay were carried out simultaneously. Biological
infection of all the ﬁnal products, which the turbid samples were
excluded, was denied and the sensitivity of endotoxin was nega-
tive at all points by gel-clot method of LAL assay in this study. To
clarify biological contamination of fungi and bacteria in process,
culture vessels for each batch were checked brieﬂy and almost
daily. The visual turbidity test was conducted when the color of
culture medium was different from the usual. Eighteen cases
(0.06%) were detected through the visual turbidity test, and
contamination was conﬁrmed in all turbid samples (Table 2).
Contamination occurred in ﬁve cases during the early phase, and
in 13 cases during the middle phase. There were no cases of
contamination in the late phase. All contaminated products were
detected before shipment by visual turbidity test as well as sterility
test. Meanwhile, no fungi or bacteria were detected on checking of
each peripheral blood.
3.2. Identiﬁcation of proliferating fungi and bacteria in the
contaminated cases
Identiﬁcation of the source of contamination was carried out
(Table 3). In only one case (No. 6), the fungus Candida guilliermondii
was observed as the likely pathogenic. All other contaminations
were caused by general bacteria, indigenous to humans. The most
commonly found bacteriawere the Staphylococcus genus conﬁrmed
in eight cases. Staphylococcus normally resides on the skin and
mucous membranes of humans. Citrobacter, Enterococcus, Klebsiella
pneumoniae, Escherichia coli, and Enterobacter constitute part of the
gut ﬂora, whilst Pseudomonas aeruginosa, Acinetobacter, E. coli, and
Enterobacter also exist in the natural environment, such as in soil or
water.
4. Discussion
From the 29,858 cell-processing batches collected as a blood
raw material in this study, the possibility of contamination was
measured at 0.06%. The Red Cross Society of Japan has reported that
the past bacterial positive rate for blood transfusion preparations,
containing the ﬁrst collected blood, was also 0.06% [7]. This
is considered to be low because of the quality management
employed according to the good manufacturing practice (GMP)
under the pharmaceutical law. Of note, Tanokuchi et al. reportedTable 1
Activated immune cell manufacturing performance in BIJ.
Activated immune cells Year Total
2010 2011 2012 2013 2014
Natural killer (NK) 3722 3017 3427 3660 3059 16,885
Others 3339 2241 2612 2710 2071 12,973
Subtotal 7061 5258 6039 6370 5130 29,858the possibility of bacterial contamination at a university hospital in
Japan as being 0.18% positive [8]. In the present study, additional
risks of contamination arose not only from the cell source harvested
from patients but also from the long-term processing for cell
expansion, suggesting that a contamination risk of 0.06% is low
enough to make a clinical application. Interestingly, it cannot be
denied that the mononuclear cells processed in this study reduced
the possibility of contamination because of the presence of white
cells in the blood that are reported to impede bacterial contami-
nation [9,10].
The phase of timing was classiﬁed by the risk analysis (Table 4).
The early phase is a primary period, which has extrinsic risk op-
erations at the cell isolation and the passage in culture. Murphy
et al. reported that contamination of collected blood occurred after
4 days storage [11], that an interfusion at blood collection could
not be detected at the early phase. The middle phase is a period for
stabilization, which has operations for passage to change vessels
from a ﬂask to a culture bag. The possible cause is both intrinsic
and extrinsic contamination. The late phase is the period for pro-
liferative process in a culture bag after conﬁrmation of logarith-
mically increase of cells. The possibility of contamination is low
since all the operations in this period are to add culture medium
using a semi-closed tubing circuit, whereas the risk is extrinsic
only.
In the early phase, ﬁve cases of contamination were observed,
and all of which were detected as common bacteria found in the
human intestines. This suggests that bacteria that reside on the skin
of the patient would not be detected by visual observation owing to
the low sensitivity against small quantities of bacteria such as skin
ﬂora, which originated from the venipuncture plug [12]. These
conﬁrmed intestinal bacteria likely existed in the blood of the pa-
tients prior to blood collection, resulting from the occurrence of
sepsis caused by medical/cancer treatments. To prevent the
contamination caused by microorganisms existing in blood, it is
necessary to add bacteriostatic activity at the cell expansion pro-
cedure in correspondence to high-risk patients.
During the middle phase, two major contamination risks pro-
cedures are considered as shown in Table 4. One is the intrinsic
contamination in raw materials contaminated by an existence in
blood or an interfusion from the patients' skin during harvesting;
the other is extrinsic risks from the external environment,
including the operators during cell processing. The turbid state
caused by the venipuncture plug is considered to occur after 4
days or later, moreover the incident in this study has a low
probability. In addition, C. guilliermondii (case No. 6) and Klebsiella
pneumonia (case No. 8) shown in Table 3 are likely intrinsic con-
taminants in the blood because No. 6 was likely pathogenic and
No. 8 is an intestinal bacterium observed in the initial early phase.
Therefore the majority of contaminated sources, which is detected
at the middle phase, are intrinsic in the raw materials. The
Staphylococcus genus found in eight cases is considered to be
intrinsic owing to interfusion at the point of blood collection, and
the other conﬁrmed bacteria were also considered intrinsic either
from the blood or the interfusion, because no occurrences of
Table 3
Identiﬁcation of microorganisms in the observed contamination cases.
No. Times of the manufacturing Days of turbid state observed Phase of the process Conﬁrmed microorganisms Classiﬁcation of microorganisms
1 2010 Mar 7 days Middle phase Staphylococcus sp. Gram-positive bacteria
2 Apr 9 days Middle phase Staphylococcus sp. Gram-positive bacteria
3 May 8 days Middle phase Staphylococcus sp. Gram-positive bacteria
4 2011 Apr 7 days Middle phase Pseudomonas aeruginosa Gram-negative bacteria
5 Jul 3 days Early phase Citrobacter freundii & Acinetobacter sp. Both gram-negative bacteria
6 Oct 7 days Middle phase Candida guilliermondii Fungi
7 Nov 2 days Early phase Enterococcus Gram-positive bacteria
8 Dec 5 days Middle phase Klebsiella pneumoniae Gram-negative bacteria
9 2012 Jan 8 days Middle phase Acinetobacter sp. Gram-negative bacteria
10 Mar 6 days Middle phase Staphylococcus epidermidis Gram-positive bacteria
11 Apr 6 days Middle phase Coagulase-negative Staphylococci Gram-positive bacteria
12 Sep 8 days Middle phase Staphylococcus epidermidis Gram-positive bacteria
13 Nov 7 days Middle phase Staphylococcus epidermidis Gram-positive bacteria
14 2013 May 2 days Early phase Klebsiella pneumoniae Gram-negative bacteria
15 Oct 1 day Early phase Escherichia coli Gram-negative bacteria
16 Dec 1 day Early phase Escherichia coli Gram-negative bacteria
17 2014 Apr 8 days Middle phase Enterobacter cloacae Gram-negative bacteria
18 Jun 7 days Middle phase Staphylococcus epidermidis Gram-positive bacteria
Table 4
Risk analysis of the activated immune cell manufacturing process.
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cannot be denied completely that the contamination occurred in
the isolation process of mononuclear cells because the isolation
procedure is the most high-risk operation in the processes of cell
expansion. The results of the late phase suggest that the risk of
extrinsic contaminated sources in the manufacturing process is
low.
In this study, all contaminations were observed in early and
middle phases, suggesting likely intrinsic contamination risk
following medical treatment prior to blood collection. Further-
more, the extrinsic contamination risks were considered to be
controlled sufﬁciently with proper aseptic processing and
changeover methods under the certiﬁcated procedures. Thus, all
the contaminations were caused by primary contamination
following medical treatments prior to blood collection, and the
risk of cross-contamination by secondary contamination could be
prevented. This suggests that airtight culture vessels including
culture ﬂasks and bags, which have openings to make small and
limited aperta at the aseptic area, can help to reduce both sec-
ondary and the extrinsic contamination risks effectively. However,this doesn't imply complete elimination of extrinsic contamina-
tion, because the conﬁrmed fungi and bacteria were able to pro-
liferate at 37 C in the cell culture medium with the blood
mononuclear cells. Consequently, the sterility test of the ﬁnal
products should be performed by low volume sampling, based on
quality management.
5. Conclusions
In this study, incidences of contaminated sources were evalu-
ated to identify contamination risks during the manufacturing
process of activated immune cells, performed in one company over
5 years. The incidence of contamination (0.06%) was relatively low,
and the occurrence of cross-contamination (secondary contami-
nation risks) could be eliminated. This suggested that most of the
contaminated sources were due to intrinsic microorganisms in the
donor patient raw materials. The secondary or extrinsic contami-
nation risks could be reduced by adequate management of the
aseptic environment and operational procedures including aseptic
processing and changeover.
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